 -- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDAs Real-Time Oncology Review RTOR Program, Expected in Second Half of 2022 -- -- New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors -- 